A rare gastrointestinal cancer is rising sharply among Gen X and Millennials, prompting experts to call for more research.

The expansion of cancer research in the Newark region will also be heightened through the relationship with the Rutgers New ...

Experts worry about the uptick in cases as more Gen Xers and millennials are being diagnosed with a variety of ...

The FDA has approved a revised label for Merck’s immunotherapy drug Keytruda, limiting its use in some gastrointestinal cancer treatments to patients whose tumors express a minimum level of PD-L1 ...

Researchers at Seoul National University Hospital applied 'Enhanced Recovery After Surgery (ERAS)' to gastric cancer surgery ...

Rates of appendiceal adenocarcinoma more than tripled among Americans born in 1980 compared with those born in 1945, a study ...

A team of researchers at the University of Minnesota recently completed a human trial for a novel gene-editing treatment, ...

Durvalumab is an IV drug that boosts the immune system’s ability to detect and kill cancer cells. It’s used to treat a range ...

Only 6 percent of patients carried a concerning DPYD variant, but nearly two-thirds of them were later hospitalized after ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

Esophageal cancer remains one of the world's deadliest cancers, ranking 7th in incidence and 6th in cancer-related deaths ...